View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c45155) has announced the addition of Triple Analysis: Non Small Cell Lung Cancer Lung Cancer, Small Cell Definition Small cell lung cancer is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description Lung cancer is divided into two main types: small cell and non-small cell. , Protein Kinase Inhibitors & Anti-Angiogenic Agents to their offering. In this triple analysis report we have analyzed three major and intertwined areas of cancer R&D, Non Small Cell Lung Cancer Therapeutics, Protein Kinase Inhibitors and Anti-angiogenesis and Vascular Targeting in Oncology, which are all subjects to an extensive number of innovative drug candidates. This extensive 280+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors. Lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. is the third most common malignant disease and the first leading cause of cancer death in the western world. The third-generation chemotherapeutic agents This is a list of specific pharmacologic agents that are known to be of use in the treatment of cancer, otherwise known as chemotherapeutic agents. This list is organized by "type" of agent, though the subsections are not necessarily definitive and are subject to revision. have expanded the therapeutic options in the treatment of advanced NSCLC NSCLC non (or cancer). NSCLC Non-small cell lung cancer, see there . However, despite their contributions, science has reached a therapeutic plateau. Both Avastin and Efaproxyn have generated exciting data. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analysed. NSCLC Highlights: * Explore the strengths and weaknesses associated with compounds in clinical development. * Scientific rationale for novel therapeutics in lung cancer, and the results of clinical trials to date. * Gain insight into the current challenges and commercial opportunities associated with lung cancer * The number of protein kinase inhibitor (PKI (Public Key Infrastructure) A framework for creating a secure method for exchanging information based on public key cryptography. The foundation of a PKI is the certificate authority (CA), which issues digital certificates that authenticate the identity of ) drugs has risen sharply, as the number of targets. The fiercest competition in PKI drug development is found in breast, lung, leukemia, prostate, and colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. . Several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline. Protein Kinase Inhibitors in Oncology Highlights: * Drugs according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. protein kinase protein kinase /pro·tein ki·nase/ (pro´ten ki´nas) an enzyme that catalyzes the phosphorylation of serine, threonine, or tyrosine groups in enzymes or other proteins, using ATP as a phosphate donor. target; Dual or multiple kinase inhibitor analysis * Targets according to indication * Competitive landscape assessment * Protein kinase inhibitors on market * Thorough review of the seven largest cancer indications in the field of protein kinase inhibitors * With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes based on tumor growth drivers rather than primary tumor primary tumor A neoplasm which, in clinical parlance, is regarded as malignant, arising in one site and capable of giving rise to metastatic or secondary tumors. See Metastasis. Cf Tumor of unknown origin. site, the use of targeted therapies, such as anti-angiogenesis, will occur in combination with traditional cytotoxic cy·to·tox·ic adj. Of, relating to, or producing a toxic effect on cells. cy  to·tox·ic chemotherapy agents. Anti-angiogenesis and Vascular Targeting Agents in Oncology Highlights * In-depth competitive landscape assessment of the anti-angiogenesis market in oncology * Thorough review of utilized targets in anti-angiogenic and vascular target drug development * Thorough review of approved drugs * Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls Content Outline: 1 Executive Summary 2 Table of Contents 3 Methodology 4 Protein Kinase Inhibitors 5 Anti-Angiogenesis & Vascular Targeting 6 Non Small Cell Lung Cancer 7 Progress in Current Treatment Strategies 8 Key Drug Strategies in Lung Cancer 9 Competitive Landscape in Non Small Cell Lung Cancer Drug Development: The Late Stage Pipeline 10 Disclaimer 11 Appendix I: Complete List of Angiogenic angiogenic /an·gio·gen·ic/ (-jen´ik) 1. pertaining to angiogenesis. 2. of vascular origin. angiogenic adjective Relating to angiogenesis and Vascular Target Agents in Development in Oncology 12 Appendix II: Treatment Guide Lines 14 Company Index 15 Drug Index 2.1 List of Boxes 2.2 List of Figures 2.3 List of Tables Companies & Products Mentioned * Novartis * AstraZeneca * Pfizer * GlaxoSmithKline * Docetaxel * Vinorelbine * Gemcitabine * Paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); * Pemetrexed * Gefitinib * Erlotinib For more information visit http://www.researchandmarkets.com/reports/c45155 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion